HSP90AA1 and systemic lupus erythematosus: This anti-Hsp90 therapy has been successfully applied in murine models of encephalomyelitis, collagen-induced arthritis, adjuvant-induced arthritis, systemic lupus erythematosus (SLE), lipopolysaccharide-induced uveitis (EIU), and DSS-induced ulcerative colitis [10,29].